-
Guangdong Junhou Biomedicine Co., Ltd. won the ISO9001 quality management system certificationOn October 27, 2022, Guangdong Junhou Biopharmaceutical Co., LTD., a wholly-owned subsidiary of Shenzhen Cell Valley Biopharmaceutical Co., LTD. (hereinafte...01-15 -
Shi Yuanyuan was invited to attend the closed-door meeting of industry leaders at the 2022 Shenzhen International Biomedical Industry Innovation and Development ConferencOn the afternoon of November 2, Shi Yuanyuan, chairman of our company, was invited to attend the closed-door meeting of industrial leaders of the 2022 Shenzhen ...01-15 -
Help NK cell therapy - Shenzhen Cell Valley and Enkesai reach a comprehensive strategic cooperationFrom September 26 to 27, 2022, Professor Shi Yuanyuan, Chairman of Shenzhen Cell Valley Biomedicine Co., LTD., Professor Wang Jianxun, Chief scientist of Shenzh...01-15 -
Shenzhen Cell Valley and Lu Daopei Medical Group to carry out in-depth cooperationRecently, Dr. Shi Yuanyuan, Chairman of the Company, met with Ms. Zhao Yi, Chief Operating Officer of Lu Daopei Medical Group, Mr. CAI Peng, General Manager of ...01-15 -
Professor Shi Yuanyuan was invited to visit the Interventional and Cell Therapy Center of Peking University Shenzhen HospitalRecently, Professor Shi Yuanyuan, founder and chairman of Shenzhen Cell Valley Biomedicine Co., LTD., Yang Bolui, Executive President of Guangdong Junhou Biomed...01-15 -
Director Yao Hong and his delegation from the Tumor Biotherapy Center of Yunnan Cancer Hospital visited Shenzhen Cell ValleyOn December 22nd, Professor Yao Hong, Director and Doctoral Supervisor of the Tumor Biotherapy Center at Yunnan Cancer Hospital (Peking University Cancer Hosp...01-10

